Hepatic Disease

Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.

Your daily dose of clinical news you may have missed.

In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .

Your daily dose of clinical news you may have missed.

The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.

Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.

Your daily dose of clinical news you may have missed.

A population-based study found metabolic dysfunction more prevalent than ultrasonographic steatosis in patients recovered from HCV and a better predictive tool for disease progression.

Risk of T2D was reduced by 49% over a 10-year follow up period among study participants who followed a vigorous or moderate exercise plan vs those who did not engage in exercise.

Your daily dose of clinical news you may have missed.

Adults with T2D may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to findings from a retrospective analysis.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Find a compact sampling of 2022 cardiovascular disease research reviewed on Patient Care, chosen by the editorial staff.

Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

Timely initiation of DAA treatment, regardless of insurance type, is crucial in reducing HCV-related death, disparity, and transmission, concluded CDC researchers.

A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.

Clinical research into treatments for NASH is hampered by the need for invasive biopsies but a new blood test using 2 biomarkers could be a game changer, say study authors.

An overview of recommendations from the American Association of Clinical Endocrinology for the management of NAFLD in adults.

Get an overview of the recent AACE guidelines for diagnosing NAFLD in adults in primary care settings.

Results of the prespecified analysis from the REGENERATE trial confirm 2019 data demonstrating statistically significant improvement in fibrosis without worsening NASH.

The sodium-glucose cotransporter 1/2 inhibitor at 150 mg was associated with a significant 32% reduction in liver enzyme levels in a phase 2a clinical trial.

How prevalent is NAFLD worldwide? What is the preferred treatment? And more questions to test your NAFLD knowledge.

Integrating NAFLD as a diabetes complication to be addressed during routine cycles of care could reduce barriers to a NAFLD pathway in primary care, agreed focus group participants.